Cargando…

Clinical utility of eslicarbazepine: current evidence

Eslicarbazepine acetate (ESL) is a new antiepileptic drug whose mechanism of action is blockade of the voltage-gated sodium channel (VGSC). However, in respect to carbamazepine and oxcarbazepine, the active ESL metabolite (eslicarbazepine) affects slow inactivation of VGSC and has a similar affinity...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zaccara, Gaetano, Giovannelli, Fabio, Cincotta, Massimo, Carelli, Alessia, Verrotti, Alberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4330027/ https://www.ncbi.nlm.nih.gov/pubmed/25709402 http://dx.doi.org/10.2147/DDDT.S57409

Ejemplares similares

Eslicarbazepine acetate in the treatment of adults with partial-onset epilepsy: an evidence-based review of efficacy, safety and place in therapy
por: Lattanzi, Simona, et al.
Publicado: (2018)

Update on the role of eslicarbazepine acetate in the treatment of partial-onset epilepsy
por: Tambucci, Renato, et al.
Publicado: (2016)

Eslicarbazepine acetate in post‐stroke epilepsy: Clinical practice evidence from Euro‐Esli
por: Sales, Francisco, et al.
Publicado: (2020)

Eslicarbazepine acetate: its effectiveness as adjunctive therapy in clinical trials and open studies
por: Shorvon, S. D., et al.
Publicado: (2017)

Eslicarbazepine acetate as adjunctive therapy in clinical practice: ESLADOBA study
por: Chaves, J., et al.
Publicado: (2017)

Healthcare Resource Utilization Pre- and Post-Initiation of Eslicarbazepine Acetate Among Pediatric Patients with Focal Seizure: Evidence from Routine Clinical Practice
por: Mehta, Darshan, et al.
Publicado: (2020)

Role of eslicarbazepine in the treatment of epilepsy in adult patients with partial-onset seizures
por: Brown, Martin E, et al.
Publicado: (2010)

Impulsivity Traits in Parkinson's Disease: A Systematic Review and Meta‐Analysis
por: Giovannelli, Fabio, et al.
Publicado: (2023)

A Review of Eslicarbazepine Acetate for the Adjunctive Treatment of Partial-Onset Epilepsy
por: Singh, Rajinder P., et al.
Publicado: (2011)

Update on treatment of partial onset epilepsy: role of eslicarbazepine
por: Rauchenzauner, Markus, et al.
Publicado: (2010)

Eslicarbazepine acetate for the treatment of focal epilepsy: an update on its proposed mechanisms of action
por: Soares-da-Silva, Patrício, et al.
Publicado: (2015)

Real‐world data on eslicarbazepine acetate as add‐on to antiepileptic monotherapy
por: Holtkamp, M., et al.
Publicado: (2016)

Dibenzazepine Agents in Epilepsy: How Does Eslicarbazepine Acetate Differ?
por: Lawthom, Charlotte, et al.
Publicado: (2018)

Eslicarbazepine Acetate Modulates EEG Activity and Connectivity in Focal Epilepsy
por: Pellegrino, Giovanni, et al.
Publicado: (2018)

Clinical utility of trabectedin for the treatment of ovarian cancer: current evidence
por: Mascilini, Floriana, et al.
Publicado: (2014)

Psychiatric adverse events in three phase III trials of eslicarbazepine acetate for focal seizures
por: Altalib, Hamada, et al.
Publicado: (2022)

New and Emerging Treatments for Epilepsy: Review of Clinical Studies of Lacosamide, Eslicarbazepine Acetate, Ezogabine, Rufinamide, Perampanel, and Electrical Stimulation Therapy
por: Chung, Steve S., et al.
Publicado: (2011)

Exposure‐safety and efficacy response relationships and population pharmacokinetics of eslicarbazepine acetate
por: Gidal, B. E., et al.
Publicado: (2018)

Transition from oxcarbazepine to eslicarbazepine acetate: A single center study
por: Mäkinen, Jussi, et al.
Publicado: (2017)

Eslicarbazepine‐induced severe hyponatremia resulted in generalized tonic‐clonic seizure
por: Habib, Mhd Baraa, et al.
Publicado: (2021)

Eslicarbazepine Acetate: A New Improvement on a Classic Drug Family for the Treatment of Partial-Onset Seizures
por: Galiana, Graciana L., et al.
Publicado: (2017)

Safety, Tolerability and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy in Patients Aged ≥ 65 Years with Focal Seizures
por: Costa, Raquel, et al.
Publicado: (2018)

Neurophysiological Correlates of Central Fatigue in Healthy Subjects and Multiple Sclerosis Patients before and after Treatment with Amantadine
por: Santarnecchi, Emiliano, et al.
Publicado: (2015)

Cutaneous adverse drug reaction type erythema multiforme major induced by eslicarbazepine
por: Massot, Andreu, et al.
Publicado: (2014)

Inhibitory Effect of Eslicarbazepine Acetate and S-Licarbazepine on Na(v)1.5 Channels
por: Leslie, Theresa K., et al.
Publicado: (2020)

Efficacy and tolerability of eslicarbazepine acetate as monotherapy in patients of newly diagnosed focal epilepsy
por: Saxena, S., et al.
Publicado: (2021)

Eslicarbazepine acetate is porphyrogenic and should be used with caution in patients with the acute hepatic porphyrias
por: Ma, Christopher D., et al.
Publicado: (2022)

Efficacy of Tocilizumab in Limbic Encephalitis with Anti-CASPR2 Antibodies
por: Benucci, Maurizio, et al.
Publicado: (2020)

Severe myoclonic epilepsy of infancy: Seizure reduction during adjunctive eslicarbazepine in two cases()
por: Buoni, Sabrina, et al.
Publicado: (2015)

Conversion to eslicarbazepine acetate monotherapy: A pooled analysis of 2 phase III studies
por: Sperling, Michael R., et al.
Publicado: (2016)

Development of a stress induced validated UPLC-PDA method for the analysis of Eslicarbazepine acetate
por: Iram, Farah, et al.
Publicado: (2018)

The pharmacokinetic, safety, and tolerability profiles of eslicarbazepine acetate are comparable between Korean and White subjects
por: Hwang, Sejung, et al.
Publicado: (2022)

Monitoring And Managing Depression In Adolescents With Epilepsy: Current Perspectives
por: Coppola, Giangennaro, et al.
Publicado: (2019)

Clinical utility of ulipristal acetate for the treatment of uterine fibroids: current evidence
por: Trefoux Bourdet, Alice, et al.
Publicado: (2015)

Clinical utility of apixaban in the prevention and treatment of venous thromboembolism: current evidence
por: Zalpour, Ali, et al.
Publicado: (2014)

Comments on the Eslicarbazepine Acetate Section of the Article ‘Therapeutic Drug Monitoring of the Newer Anti-Epilepsy Medications’
por: Öztiryaki, Ahmet H., et al.
Publicado: (2010)

Development and Validation of an RP-HPLC Method for Quantitative Estimation of Eslicarbazepine Acetate in Bulk Drug and Tablets
por: Singh, M., et al.
Publicado: (2013)

Adjunctive Treatment With Eslicarbazepine Acetate for Adults and Children With Focal-Onset Epilepsy: A Meta-Analysis
por: Fei, Yanqing, et al.
Publicado: (2022)

Evaluation of the Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Perampanel in Rats by Isotope-Dilution-UHPLC-MS/MS
por: Liu, Ping, et al.
Publicado: (2022)

Long‐term efficacy and safety of eslicarbazepine acetate monotherapy for adults with newly diagnosed focal epilepsy: An open‐label extension study
por: Trinka, Eugen, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7hoq1o6a2cn7v9h0ejjssm05af